In the first published study of its kind, Tonalin® CLA improved airway hyper-reactivity in overweight mild asthmatics accompanied by a significant improvement in their tolerance for strenuous exercise 1.
Adults taking Tonalin® CLA also reduced their body weight and BMI by 2 kg (4.4 lbs) and 0.5 kg/m2 over time which was associated with a metabolically favorable change in adipokine concentrations. The reductions observed in the CLA group were significantly different from the placebo group confirming once again the beneficial impact of CLA for weight and body fat management.
The prospective, randomized, double-blind, placebo-controlled intervention trial, published in the July edition of the Journal of Clinical & Experimental Allergy, was conducted by a team of researchers at the University of British Colombia, Vancouver, Canada. In the 12-week study, supplementation of Tonalin® CLA was an adjunct to usual care in overweight asthmatics and was well tolerated. The 28 mildly asthmatic men and women were randomized to consume 4.5 grams daily of Tonalin® CLA or a placebo.
In their discussion, researchers stated that CLA could be beneficial for asthma treatment for a number of reasons. Diets rich in milk fat, an important source of CLA, have been associated with a lower risk of asthma symptoms 2,3. Biological activities of CLA including the regulation of inflammation 4-6 and reduction of body fat mass 7 are described as consistent with the potential benefits in asthma.
According to the researchers, “A huge number of asthma patients seek complementary therapies, and a wide range of products are marketed as 'asthma treatments', frequently with no evidence. CLA is safe, in our studies and in others, clinically effective and may be considered for overweight mild astmatics seeking natural remedies as part of their asthma management plan. We encourage further studies to elucidate the role of CLA in a broader asthma population."
Christina Ehrhardt, Global Research Manager, Cognis Nutrition & Health, said this research adds important new insights into the totality of evidence supporting the overall health and body composition benefits of Tonalin® CLA.
Tonalin® is the most clinically tested CLA brand, having been used in the majority of human trials on body composition. Tonalin® is derived from safflowers using a proprietary process to create the highest quality of commercially available CLA. A naturally sourced product, it comes in several forms, such as oil and water-dispersible powder, making it suitable for applications in food, beverages and dietary supplements. Potential food applications include, milk and yogurt products, processed fruit and fruit juices, coffee creamers, soy milk beverages, chocolate and meal replacement beverages and bars.
Recently, Tonalin® CLA received Novel Food approval in China. In July 2008, Cognis achieved the US FDA GRAS status for Tonalin® CLA. Cognis has also applied for Novel Food approval in Europe and expects to gain approval there later this year. Tonalin®CLA is an exclusively licensed product of the Cognis Group.
1 MacRedmond R et al. (2010). Clin Exp Allergy, 2010 (40) 1071–1078
2 Wijga RK et al. (2003). Thorax 58 : 567-572
3 Woods RK et al. (2003). Am J Clin Nutr 78 : 414-421
4 Urquart P et al. (2002). Biochem Biophys Acta 1580: 150-156
5 Pariza MW et al. (2000). Proc Soc Esp Biol Med 223 : 8-13
6Jaudszus A et al. (2008). J Nutr 138: 1336-1342
7 Whigham LD et al. (2007). Am J Clin Nutr 85: 1203-1211
Cognis is a worldwide supplier of specialty chemicals and nutritional ingredients, with a particular focus on the areas of wellness and sustainability. The company employs about 5,500 people, and it operates production sites and service centers in 30 countries. Cognis has dedicated its activities to a high level of sustainability and provides value adding solutions and products based on renewable raw materials. The company serves the food, nutrition and healthcare markets, and the cosmetics, detergents and cleaners industries. Another main focus is on products for a number of other industries, such as coatings and inks, lubricants, as well as agriculture and mining.
Cognis is currently owned by private equity funds advised by Permira, GS Capital Partners, and SV Life Sciences. In 2009, Cognis recorded sales of about 2.6 billion euros and an Adjusted EBITDA (operating result) of 364 million euros.